Information contained on this page is provided by companies via press release distributed through PR Newswire, an independent third-party content provider. PR Newswire, WorldNow and this Station make no warranties or representations in connection therewith.
SOURCE GC-Rise Pharmaceutical Co., Ltd
BEIJING, March 18, 2013 /PRNewswire/ -- GC-Rise Pharmaceutical Co. Ltd, in which European healthcare venture capital firm INVENTAGES holds a majority stake, attracted the attention of investors at the annual China Healthcare Investment Conference in Shanghai.
Beijing-headquartered GC-Rise, which focuses on women's and children's health in China, took the opportunity to showcase its growth stories and seek tie-ups with partners from the most promising public and private Chinese healthcare companies.
The conference was held from March 12-14 in Shanghai. GC-Rise presented the company's growth roadmap and new initiatives for 2013 at the event last Thursday.
On top of the new moves, the pediatrics pharmaceutical market has been incorporated into GC-Rise's specialties, reshaping the company's five strategic focuses into anti-aging products, respiratory diseases in children, pregnancy & new born health, skin care products, and mental health & child development.
"The market size of GC-Rise's strategic focus in China's women's and children's health is expected to see compound annual growth rate of 28% over the period of 2010-2017 due to growing healthcare awareness," said Wren Zhang, the Strategic Director of GC-Rise.
Furthermore, GC-Rise will foray into point-of-care testing (POCT) in the OB-GYN & pediatrics market taking advantages of the company's broad commercial channels and close connections with physicians.
"Technical advancements have helped the POCT market grow at a double digit CAGR from 2009 to 2011, which is expected to reach US$25 billion worldwide by 2016, while China will be one of the fastest growth drivers," Wren said.
GC-Rise, founded in 2008, has seen rapid growth over five years of continuous expansion. The company has been listed in the top 50 fast-growing companies in China by Deloitte for two consecutive years in 2011 and 2012 as the only pharmaceutical enterprise.
The company also initiated the country's first GYN/OB Physician Award in China joining hands with China Physician Association in 2012.
China Health Care Investment Conference is organized by a group of investors including KPCB, Fidelity Asia Ventures, Vivo Ventures and Piper Jaffray. The group is committed to turn this meeting into a powerful platform to promote and nurture the Chinese healthcare investment ecosystem and further develop the industry.
About GC-Rise Pharmaceutical Co. Ltd
GC-Rise Pharmaceutical Co. Ltd, established in 2008, is invested in by INVENTAGES Venture Capital and Yifang Venture Capital. Taking "Innovation for human health and a better life" as mission, the company makes full use of the business networks of strategic partners in the United States, Europe and Japan, to provide safe, novel and highly efficient medical products and treatment ideas for Chinese women and children patients.
Please log on http://www.gc-rise.com/ to know more information.
©2012 PR Newswire. All Rights Reserved.